This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Kevin Fiscella, MD; Peter Franks, MD

JAMA. 1996;275(16):1247-1251.

Abstract
Objective.
—To determine the incremental cost-effectiveness of the transdermal nicotine patch.

Design.
—Decision analytic model that evaluated the incremental cost-effectiveness of the addition of the nicotine patch to smoking cessation counseling. Costs were based on physician time and the retail cost of the nicotine patch, and benefits were based on quality-adjusted life years (QALYs) saved.

Patients.
—Male and female smokers aged 25 to 69 years receiving primary care.

Intervention.
—Addition of the nicotine patch to physician-based smoking cessation counseling.

Main Outcome Measure.
—Costs (1995 dollars) per QALYs saved discounted by 3% annually.

Results.
—The use of the patch produced 1 additional lifetime quitter at a cost of $7332. The incremental cost-effectiveness of the nicotine patch by age group ranged from $4390 to $10 943 per QALY for men and $4955 to $6983 per QALY for women. A clinical strategy involving limiting prescription renewals to patients successfully abstaining for the first 2 weeks improved the cost-effectiveness of the patch by 25%.

Conclusions.
—The findings provide support both for the routine use of the nicotine patch as an adjunct to physicians' smoking cessation counseling and for health insurance coverage of nicotine patch therapy.

(JAMA. 1996;275:1247-1251)

Author Affiliations
From the Primary Care Institute, Highland Hospital, Department of Family Medicine, University of Rochester (NY) School of Medicine and Dentistry.

Footnotes
Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A review of the cost-effectiveness of face-to-face behavioural interventions for smoking, physical activity, diet and alcohol
Gordon et al.
Chronic Illness 2007;3:101-129.
ABSTRACT  

Cost-effectiveness analyses and modelling the lifetime costs and benefits of health-behaviour interventions
Graves et al.
Chronic Illness 2006;2:97-107.
ABSTRACT  

Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison
Cornuz et al.
Tobacco Control 2006;15:152-159.
ABSTRACT | FULL TEXT  

A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children
Johansson et al.
Scand J Public Health 2005;33:343-352.
ABSTRACT  

Peer-Delivered Smoking Counseling for Childhood Cancer Survivors Increases Rate of Cessation: The Partnership for Health Study
Emmons et al.
JCO 2005;23:6516-6523.
ABSTRACT | FULL TEXT  

Systematic Review of Economic Evaluations of Smoking Cessation: Standardizing the Cost-Effectiveness
Ronckers et al.
Med Decis Making 2005;25:437-448.
ABSTRACT  

Cost effectiveness of a community based research project to help women quit smoking
Secker-Walker et al.
Tobacco Control 2005;14:37-42.
ABSTRACT | FULL TEXT  

The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles
Gilbert et al.
Tobacco Control 2004;13:190-195.
ABSTRACT | FULL TEXT  

The pharmacoepidemiology of COPD: Recent advances and methodological discussion
Eur Respir J 2003;22:1s-44s.
FULL TEXT  

The burden of illness and economic evaluation for COPD
Ramsey and Sullivan
Eur Respir J 2003;21:29S-35s.
ABSTRACT | FULL TEXT  

References
Circulation 2002;106:3373-3421.
FULL TEXT  

Cost-Effectiveness of Pharmacological Interventions for Smoking Cessation: a Literature Review and a Decision Analytic Analysis
Song et al.
Med Decis Making 2002;22:S26-S37.
ABSTRACT  

Task Force #2--the cost of prevention: can we afford it? Can we afford not to do it?
Krumholz et al.
J Am Coll Cardiol 2002;40:603-615.
FULL TEXT  

Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease
Briggs et al.
Med Decis Making 2002;22:290-308.
ABSTRACT  

Cigarette consumption and sales of nicotine replacement products
Hu et al.
Tobacco Control 2000;9 :ii60-ii63.
ABSTRACT | FULL TEXT  

New Developments in Smoking Cessation
Prochazka
Chest 2000;117 :169S-175S.
ABSTRACT | FULL TEXT  

Pharmacotherapy of Smoking Cessation
Okuyemi et al.
Arch Fam Med 2000;9:270-281.
ABSTRACT | FULL TEXT  

Recent advances: Pulmonary medicine
Roche
BMJ 1999;318:171-176.
FULL TEXT  

Use and Cost Effectiveness of Smoking-Cessation Services under Four Insurance Plans in a Health Maintenance Organization
Curry et al.
NEJM 1998;339:673-679.
ABSTRACT | FULL TEXT  

Usage patterns of transdermal nicotine when purchased as a non-prescription medicine from pharmacies
Shaw et al.
Tobacco Control 1998;7:161-167.
ABSTRACT | FULL TEXT  

Cost-effectiveness of the Clinical Practice Recommendations in the AHCPR Guideline for Smoking Cessation
Cromwell et al.
JAMA 1997;278:1759-1766.
ABSTRACT  

Use of Over-the-Counter Nicotine Patch for Smoking Cessation: Prudent or Premature?
McNagny and Ahluwalia
JAMA 1996;276:371-371.
ABSTRACT  

The Ledger of Tobacco Control: Is the Cup Half Empty or Half Full?
Davis
JAMA 1996;275:1281-1284.
ABSTRACT  

Free Nicotine Replacement Therapy Programs vs Implementing Smoke-Free Workplaces: A Cost-Effectiveness Comparison
Ong and Glantz
AJPH 2005;95:969-975.
ABSTRACT | FULL TEXT